DOI: 10.1002/jhbp.1349 ISSN:

Impact of antithrombotic therapy on postpancreatectomy hemorrhage in 7116 patients: A project study by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery

Kota Nakamura, Minako Nagai, Ippei Matsumoto, Sohei Satoi, Fuyuhiko Motoi, Manabu Kawai, Yasuo Hosouchi, Ryota Higuchi, Shugo Mizuno, Takao Ohtsuka, Keiichi Akahoshi, Kenichi Hakamada, Michiaki Unno, Hiroki Yamaue, Masafumi Nakamura, Itaru Endo, Masayuki Sho
  • Hepatology
  • Surgery



We previously reported an association between antithrombotic therapy and an increased risk of postpancreatectomy hemorrhage (PPH). To validate our findings, we conducted a large‐scale multicenter retrospective study from 63 high‐volume centers in Japan.


Between 2015 and 2018, 7116 patients who underwent pancreatectomy were enrolled. The antithrombotic group consisted of 920 patients (12.9%) who received preoperative antithrombotic agents including aspirin, clopidogrel, ticlopidine, prasugrel, warfarin, and direct oral anticoagulants.


PPH occurred in 235 (3.3%) of the patients. The incidence of PPH and mortality were significantly higher in the antithrombotic group than in the control group (5.7 vs. 3.0% and 2.2 vs. 0.9%, respectively; both p < .001). In multivariate analysis, a history of antithrombotic use was an independent risk factor for grade C PPH (p = .036). In the antithrombotic group, PPH tended to be delayed in the patients with restarting antithrombotic therapy. Notably, the occurrence of delayed PPH after restarting antithrombotic therapy was observed only when antithrombotic therapy was restarted within 10 days after pancreatectomy.


This multicenter study demonstrated that a history of antithrombotic use was a significant risk factor for PPH and mortality. In particular, the resumption of antithrombotic therapy in the early postoperative period should be done with caution.

More from our Archive